Twenty Percent of New Cancer Treatments Do Not Offer a Clinical Benefit

While cancer drugs approved between 2003 and 2013 often improved quality of life, the average overall survival increase was only 3.43 months, and many drugs reduced patient safety, according to an article published in JAMA Oncology.1 It is often unclear whether a particular cancer treatment is worth the costs associated with its development and distribution. Overall survival is the standard measure by which a drug's efficacy is determined, and drug approv

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial presented at the ESMO 18th World Congress of Gastrointestinal Cancer. "Systemic treatment for hepatocellular carcinoma has long consisted of just one agent, sorafenib, which was shown to provide a significant improvement in life expectancy almost 10 years ago, bu